High Tregs levels also impaired the response to anti-PD-1/PD-L1 therapy (causing a poor immunologic response against the tumor) (Bettelli et al., 2006), and strategies involving targeting Tregs lead to improved responsiveness to anti-PD-1/PD-L1 therapy (Arce Vargas et al., 2017; Taylor et al., 2017). This evidence concerns the gene CD274 and neoplasm.